Current role of bone scan with phosphonates in the follow-up of breast cancer

Lorenzo Maffioli, Luigia Florimonte, Luca Pagani, Ivana Butti, Isabel Roca

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bone scintigraphy with radiolabelled phosphonates shows a high sensitivity in detecting breast cancer metastases. For this reason it has been considered the most useful tool for early diagnosing and monitoring the metastatic spread of breast cancer. In the past years, there has been wide debate on its impact on survival time, morbidity and quality of life. The results of some studies on the asymptomatic patients during follow-up have led to the adoption of an almost minimalist policy for breast cancer surveillance including only a few procedures (breast self-examination, history, physical examination, patient education on symptoms, and abdomen ultrasonography). The routine use of additional tests, such as tumour markers, chest X-rays, bone scintigraphy, and computed tomography (CT), has not been recommended, except in those cases with clinical suspicion or in patients at high risk of metastases. On the other hand, the early diagnosis of bone involvement may reduce the risk of skeletal-related events, thus leading to a significant improvement in quality of life and opening the options of the new therapy choices in order to plan more aggressive systemic treatments whose efficacy could have impact even on survival. Besides this, the recent development of nuclear medicine modalities, the evolution of PET and PET/CT systems has brought new elements of discussion in this area, since at present the depiction of skeletal metastases can be carried out with 99mTcphosphonates and also with 18F-PET, 18F-FDG-PET, and 18F-FDG-PET/CT. Therefore, the clinical problem today is not only when and whether bone scans should be used, but the question has also become which diagnostic modality can be used? In our opinion the choice of the modality has to consider different general and local factors such as the diagnostic accuracy, the availability, the economic costs, and so on. The most important issue is that every new diagnostic approach should be validated by large randomised prospective clinical trials with the goal to measure the effective impact on the course of the disease and on patient management. Nowadays, we do not have a sufficient amount of this kind of data, in spite of much clinical evidence that demonstrates the excellent sensitivity of bone scintigraphy in discovering skeletal metastases.

Original languageEnglish
Title of host publicationBreast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options
PublisherSpringer Berlin Heidelberg
Pages227-238
Number of pages12
ISBN (Print)9783540367802
DOIs
Publication statusPublished - 2008

Fingerprint

Organophosphonates
Breast Neoplasms
Bone and Bones
Radionuclide Imaging
Neoplasm Metastasis
Tomography
Fluorodeoxyglucose F18
Quality of Life
Breast Self-Examination
Survival
Nuclear Medicine
Patient Education
Tumor Biomarkers
Abdomen
Physical Examination
Early Diagnosis
Ultrasonography
Thorax
Randomized Controlled Trials
History

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maffioli, L., Florimonte, L., Pagani, L., Butti, I., & Roca, I. (2008). Current role of bone scan with phosphonates in the follow-up of breast cancer. In Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options (pp. 227-238). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-36781-9_18

Current role of bone scan with phosphonates in the follow-up of breast cancer. / Maffioli, Lorenzo; Florimonte, Luigia; Pagani, Luca; Butti, Ivana; Roca, Isabel.

Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, 2008. p. 227-238.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maffioli, L, Florimonte, L, Pagani, L, Butti, I & Roca, I 2008, Current role of bone scan with phosphonates in the follow-up of breast cancer. in Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, pp. 227-238. https://doi.org/10.1007/978-3-540-36781-9_18
Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. In Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg. 2008. p. 227-238 https://doi.org/10.1007/978-3-540-36781-9_18
Maffioli, Lorenzo ; Florimonte, Luigia ; Pagani, Luca ; Butti, Ivana ; Roca, Isabel. / Current role of bone scan with phosphonates in the follow-up of breast cancer. Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, 2008. pp. 227-238
@inbook{45118c5106fb4284a20de3693345b662,
title = "Current role of bone scan with phosphonates in the follow-up of breast cancer",
abstract = "Bone scintigraphy with radiolabelled phosphonates shows a high sensitivity in detecting breast cancer metastases. For this reason it has been considered the most useful tool for early diagnosing and monitoring the metastatic spread of breast cancer. In the past years, there has been wide debate on its impact on survival time, morbidity and quality of life. The results of some studies on the asymptomatic patients during follow-up have led to the adoption of an almost minimalist policy for breast cancer surveillance including only a few procedures (breast self-examination, history, physical examination, patient education on symptoms, and abdomen ultrasonography). The routine use of additional tests, such as tumour markers, chest X-rays, bone scintigraphy, and computed tomography (CT), has not been recommended, except in those cases with clinical suspicion or in patients at high risk of metastases. On the other hand, the early diagnosis of bone involvement may reduce the risk of skeletal-related events, thus leading to a significant improvement in quality of life and opening the options of the new therapy choices in order to plan more aggressive systemic treatments whose efficacy could have impact even on survival. Besides this, the recent development of nuclear medicine modalities, the evolution of PET and PET/CT systems has brought new elements of discussion in this area, since at present the depiction of skeletal metastases can be carried out with 99mTcphosphonates and also with 18F-PET, 18F-FDG-PET, and 18F-FDG-PET/CT. Therefore, the clinical problem today is not only when and whether bone scans should be used, but the question has also become which diagnostic modality can be used? In our opinion the choice of the modality has to consider different general and local factors such as the diagnostic accuracy, the availability, the economic costs, and so on. The most important issue is that every new diagnostic approach should be validated by large randomised prospective clinical trials with the goal to measure the effective impact on the course of the disease and on patient management. Nowadays, we do not have a sufficient amount of this kind of data, in spite of much clinical evidence that demonstrates the excellent sensitivity of bone scintigraphy in discovering skeletal metastases.",
author = "Lorenzo Maffioli and Luigia Florimonte and Luca Pagani and Ivana Butti and Isabel Roca",
year = "2008",
doi = "10.1007/978-3-540-36781-9_18",
language = "English",
isbn = "9783540367802",
pages = "227--238",
booktitle = "Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Current role of bone scan with phosphonates in the follow-up of breast cancer

AU - Maffioli, Lorenzo

AU - Florimonte, Luigia

AU - Pagani, Luca

AU - Butti, Ivana

AU - Roca, Isabel

PY - 2008

Y1 - 2008

N2 - Bone scintigraphy with radiolabelled phosphonates shows a high sensitivity in detecting breast cancer metastases. For this reason it has been considered the most useful tool for early diagnosing and monitoring the metastatic spread of breast cancer. In the past years, there has been wide debate on its impact on survival time, morbidity and quality of life. The results of some studies on the asymptomatic patients during follow-up have led to the adoption of an almost minimalist policy for breast cancer surveillance including only a few procedures (breast self-examination, history, physical examination, patient education on symptoms, and abdomen ultrasonography). The routine use of additional tests, such as tumour markers, chest X-rays, bone scintigraphy, and computed tomography (CT), has not been recommended, except in those cases with clinical suspicion or in patients at high risk of metastases. On the other hand, the early diagnosis of bone involvement may reduce the risk of skeletal-related events, thus leading to a significant improvement in quality of life and opening the options of the new therapy choices in order to plan more aggressive systemic treatments whose efficacy could have impact even on survival. Besides this, the recent development of nuclear medicine modalities, the evolution of PET and PET/CT systems has brought new elements of discussion in this area, since at present the depiction of skeletal metastases can be carried out with 99mTcphosphonates and also with 18F-PET, 18F-FDG-PET, and 18F-FDG-PET/CT. Therefore, the clinical problem today is not only when and whether bone scans should be used, but the question has also become which diagnostic modality can be used? In our opinion the choice of the modality has to consider different general and local factors such as the diagnostic accuracy, the availability, the economic costs, and so on. The most important issue is that every new diagnostic approach should be validated by large randomised prospective clinical trials with the goal to measure the effective impact on the course of the disease and on patient management. Nowadays, we do not have a sufficient amount of this kind of data, in spite of much clinical evidence that demonstrates the excellent sensitivity of bone scintigraphy in discovering skeletal metastases.

AB - Bone scintigraphy with radiolabelled phosphonates shows a high sensitivity in detecting breast cancer metastases. For this reason it has been considered the most useful tool for early diagnosing and monitoring the metastatic spread of breast cancer. In the past years, there has been wide debate on its impact on survival time, morbidity and quality of life. The results of some studies on the asymptomatic patients during follow-up have led to the adoption of an almost minimalist policy for breast cancer surveillance including only a few procedures (breast self-examination, history, physical examination, patient education on symptoms, and abdomen ultrasonography). The routine use of additional tests, such as tumour markers, chest X-rays, bone scintigraphy, and computed tomography (CT), has not been recommended, except in those cases with clinical suspicion or in patients at high risk of metastases. On the other hand, the early diagnosis of bone involvement may reduce the risk of skeletal-related events, thus leading to a significant improvement in quality of life and opening the options of the new therapy choices in order to plan more aggressive systemic treatments whose efficacy could have impact even on survival. Besides this, the recent development of nuclear medicine modalities, the evolution of PET and PET/CT systems has brought new elements of discussion in this area, since at present the depiction of skeletal metastases can be carried out with 99mTcphosphonates and also with 18F-PET, 18F-FDG-PET, and 18F-FDG-PET/CT. Therefore, the clinical problem today is not only when and whether bone scans should be used, but the question has also become which diagnostic modality can be used? In our opinion the choice of the modality has to consider different general and local factors such as the diagnostic accuracy, the availability, the economic costs, and so on. The most important issue is that every new diagnostic approach should be validated by large randomised prospective clinical trials with the goal to measure the effective impact on the course of the disease and on patient management. Nowadays, we do not have a sufficient amount of this kind of data, in spite of much clinical evidence that demonstrates the excellent sensitivity of bone scintigraphy in discovering skeletal metastases.

UR - http://www.scopus.com/inward/record.url?scp=84892321900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892321900&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-36781-9_18

DO - 10.1007/978-3-540-36781-9_18

M3 - Chapter

SN - 9783540367802

SP - 227

EP - 238

BT - Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options

PB - Springer Berlin Heidelberg

ER -